A completed phase II trial evaluated whether the selected drugs, sunitinib or everolimus, based on the defective gene would result in a better tumor response to patients with advanced neuroendocrine tumors, including NF1 (Clinicaltrials.gov ID: NCT02315625). The gene discussed is NF1; the disease is neoplasm.